Beijing Neox Biotech Co. Ltd. has patented proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to wee1-like protein kinase (Wee1) binding moiety through a linker reported to be useful for the treatment of cancer.